Scientists of the National Research Technical University in Moscow have created a drug that solves the problem of toxicity and cellular resistance to conventional anticancer drugs.
The media office of the university indicates that researchers have created a hybrid anti-cancer drug based on platinum compounds and vitamin B12 that targets cancer cells in two different ways when lighting its molecules with blue light flashes, reports Al-Rai daily.
The office statement read: “The drug that scientists have devised can be activated in a controlled manner only in the malignant tumor area under the influence of blue light, without affecting non-irradiated tissues, which opens up opportunities for targeted (targeting) chemotherapy.” Platinum and vitamin B12 compounds solve the problem of toxicity and cellular resistance to conventional anticancer drugs.
Platinum compounds are widely used in medicine and pharmacology to create preparations capable of destroying various types of cancer cells. Cisplatin is the most widely used anti-cancer drug.
These compounds have high efficacy in treating cancer, but they have several side effects, which scientists are trying to get rid of, or at least mitigate, by creating new platinum compounds that are able to selectively penetrate cancer cells.
Read Today's News TODAY... on our Telegram Channel click here to join and receive all the latest updates t.me/thetimeskuwait
